PetMedix has been voted best start-up in the global Animal Pharm Awards. The UK-based start-up is developing a new tier of monoclonal antibody therapy for the animal health market. Situated in the heart of the Cambridge biotechnology cluster, 2020 will see the company take up residence in the new Babraham Campus later in the year.
The Animal Pharm Awards aim to highlight innovation and growth made by companies of all sizes and from different sectors. Joseph Harvey, Editor of Animal Pharm, said: “The company’s submission was very impressive – full of information that clearly stated its achievements so far and its intentions. It was a worthy winner in this category”.
The team at PetMedix have a strong pedigree in the human monoclonal antibody space. Recognising a yawning gap in the provision of precision medicine for pets, they have adapted a world-leading transgenic approach that underpins the most successful and advanced human antibody platforms available today.
The company state the complete and intact immune system of their platform leverages the full potential of the dog’s own natural antibody repertoire – a feat not possible with alternate technologies – to maximise the safety and efficacy of its products. The result is precision drugs with higher efficacy, reduced risk of side effects and reduced immunogenicity (a property which may lower efficacy and increase risk of further side effects).
Tom Weaver, CEO, stated: “This award is welcome recognition of a year where the company secured sizeable series A funding, grew the strength of our board and added significant scientific expertise. We look forward to a continued trajectory of strong growth as we move into larger premises and continue R&D on a number of drug targets”.
